24 May 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Scancell
to present at the 2024 ASCO Annual
Meeting
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer
and infectious disease, is pleased to announce that it will be
presenting during a poster session at the American Society of
Clinical Oncology (ASCO) Annual Meeting, taking place from 31 May
to 4 June 2024, in Chicago, Illinois.
Scancell will be presenting a poster
highlighting data from its open-label Phase 2 SCOPE trial,
investigating its cancer vaccine, SCIB1, in combination with
checkpoint inhibitors (CPIs) in advanced melanoma. Exceptional
results from the first 13 patients receiving SCIB1 have already
been demonstrated, with an objective response rate of
85%.
Professor Lindy Durrant, Chief Executive Officer of Scancell,
said: "ASCO is one the leading
events for companies working in the field of oncology and so we
were very proud to be selected to present a poster at this year's
conference. Our ongoing Phase 2 SCOPE trial of our
melanoma cancer vaccine, SCIB1, has shown highly
promising efficacy and safety data so far and we are hugely excited
to highlight the progress Scancell is making in the cancer vaccine
space."
Poster presentation details
Title: A DNA plasmid melanoma
cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in
patients with advanced unresectable melanoma: Efficacy and safety
results from the open-label phase 2 SCOPE trial.
Session type and title: Poster
Session - Melanoma/Skin Cancers
Session date and time: 1 June
2024, 1:30 PM - 4:30 PM CDT
If you would like to arrange a
meeting at the conference, please contact commercial.enquiries@scancell.co.uk.
-ENDS-
|
For further
information, please contact:
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment
Banking)
|
|
|
Nick Harland / Ben Good (Corporate Broking)
|
|
|
WG Partners LLP
(Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope®
and ImmunoBody®
for vaccines and GlyMab® and
AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab®) or
enhances the potency of antibodies and their ability to directly
kill tumour cells
(AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/
